What is the efficacy of infliximab treatment for hidradenitis suppurativa (HS)?

Updated: Aug 30, 2019
  • Author: Marina Jovanovic, MD, PhD; Chief Editor: William D James, MD  more...
  • Print
Answer

Patients self-report that pain significantly decreased following infliximab treatment. This correlated with significant physician-observed clinical improvement (P = .0001). Patients reported a rapid response after the first infusion, and some of them noticed decreased pain after 24 hours. [112, 113] Although the efficacy has proven impressive and short-term adverse effects have been few and relatively benign, the long-term adverse effects have not been studied. Further multicenter studies are needed to assess effects of its prolonged use, as well as to determine safety, optimal frequency of dosing, and time to relapse after cessation of therapy. [113, 114]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!